Benitec Biopharma Inc. Common Stock

BNTCNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
12.37 USD
↘ 0.63 (4.85%)AT CLOSE (11:59 AM EDT)
12.37
↗ 0.00 (0.00%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
12.37
↗ 0.00 (0.00%)
🔴Market: CLOSED

BNTC is currently priced at $12.37. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest BNTC is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jun 26, 2026.

Open?$12.99
High?$13.52
Low?$12.17
Prev. Close?$13.00
Volume?1.0M
Avg. Volume?126.6K
VWAP?$12.69
Rel. Volume?8.07x
Bid / Ask
Bid?$10.09 × 100
Ask?$14.11 × 100
Spread?$4.02
Midpoint?$12.10
Valuation & Ratios
Market Cap?425.0M
Shares Out?34.4M
Float?21.1M
Float %?61.4%
P/E Ratio?N/A
P/B Ratio?2.32
EPS?-$1.42
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
19
Market Cap
446.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.benitec.com
Listed
2012-07-11
Address
3940 TRUST WAY
HAYWARD, CA 94545
Phone: (510) 780-0819
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?67.78Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?11.40%High
Short Interest?2.4M
Days to Cover?28.9
Free Float21.1M
Avg Daily Volume83.4K
Settlement Date2026-06-15
Financial Health
Current Ratio?56.78Strong
Quick Ratio?56.78Strong
Cash Ratio?56.43Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
68
2.32CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-26.7%WEAK▾
ROA?
S&P
3
-26.1%WEAK▾
Cash Flow & Enterprise
FCF?$-19818000
Enterprise Value?$240.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist